^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Excerpt:
...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
Source:
Title:
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Excerpt:
...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
Less C2 evidence
Source:
Title:
1647MO - BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network
Published date:
09/05/2022
Excerpt:
Among the 53 BRAF mutated pts, 21 (40%) received BRAF inhibitors: 17 Dabrafenib + Trametinib (8 as 1st line and 9 post chemotherapy (CT) with a median OS of 14.21 months (4.66-NA) and a median 1L-PFS of 6.38 months (1.79-NA), 4 were treated with Vemurafenib (1 as 1L and 3 post-CT, median OS: 14.91 months (6.88-NA)....These results confirm the clinical benefit of BRAF inhibitors in BRAF mutated ATC in a real-life population.
